DUBLIN, Oct. 15, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the sale of its women's health business to Meda (an international specialty pharmaceutical company) for $95 million in cash.
The products included in the sale are Elestrin® (estradiol gel), Gastrocrom® (cromolyn sodium, USP), Natelle® One (prenatal vitamin), AVC™ Cream (sulfanilamide), Gesticare® DHA (prenatal multi-vitamin) and Urelle® (urinary antiseptic).
For accounting purposes, the women's health business will be treated as a discontinued operation. More detail about the accounting impact of the transaction will be disclosed in pro forma financial statements filed on a Form 8-K and in the company's Form 10-Q for the quarter ended September 30, 2012.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products to meet unmet medical needs. The company's U.S. marketed products include: Xyrem® (sodium oxybate), Erwinaze™ (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine USP) HD and LD and Luvox CR® (fluvoxamine maleate). Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by an international division, EUSA Pharma. For further information, see http://www.jazzpharmaceuticals.com .
SOURCE Jazz Pharmaceuticals plc